Orgenesis announced positive clinical trial results for a real-world study of CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. Harley Street Healthcare Group intends to set up a Global Cancer Initiative through its joint venture with Orgenesis, with a focus to democratize Advance Therapies and support further clinical development. The top-line efficacy and safety data from the study had a complete response of 82% in adult patients and 93% in pediatric patients. Moreover, the incidence of severe Cytokine Release Syndrome, a common safety concern associated with CAR-T therapies, was found to be low, 2% in adult patients and 6% in pediatric patients, compared to currently approved treatments. This suggests a favorable safety profile for ORG-101. CRS is a systemic reaction caused by an exaggerated immune response to immunotherapy, which is a significant safety issue in conventional CAR-T treatments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGS:
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
- Biotech Alert: Searches spiking for these stocks today
- Orgenesis announces JV partnership with Harley Street Healthcare Group
- Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
- Orgenesis reports Q2 EPS (23c) vs. (76c) last year